VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Significant Growth in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 82,600 shares, an increase of 65.2% from the October 15th total of 50,000 shares. Based on an average trading volume of 70,400 shares, the short-interest ratio is presently 1.2 days. Currently, 0.7% of the shares of the company are sold short.

VYNE Therapeutics Price Performance

VYNE traded down $0.07 during midday trading on Thursday, reaching $2.84. 25,666 shares of the company’s stock were exchanged, compared to its average volume of 82,782. The stock has a market capitalization of $41.89 million, a PE ratio of -3.38 and a beta of 1.32. The business’s 50-day moving average price is $2.24 and its 200 day moving average price is $2.18. VYNE Therapeutics has a 1-year low of $1.57 and a 1-year high of $4.48.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.11 million. VYNE Therapeutics had a negative net margin of 6,896.55% and a negative return on equity of 43.73%. As a group, analysts expect that VYNE Therapeutics will post -0.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.75 target price on shares of VYNE Therapeutics in a report on Friday, November 8th.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Virtu Financial LLC acquired a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 16,199 shares of the company’s stock, valued at approximately $50,000. Virtu Financial LLC owned 0.11% of VYNE Therapeutics as of its most recent SEC filing. 83.78% of the stock is owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.